Literature DB >> 12200374

Effect of hyperhomocysteinemia on protein C activation and activity.

Steven R Lentz1, Donald J Piegors, José A Fernández, Rochelle A Erger, Erland Arning, M René Malinow, John H Griffin, Teodoro Bottiglieri, William G Haynes, Donald D Heistad.   

Abstract

Hyperhomocysteinemia has been proposed to inhibit the protein C anticoagulant system through 2 mechanisms: decreased generation of activated protein C (APC) by thrombin, and resistance to APC caused by decreased inactivation of factor Va (FVa). We tested the hypotheses that generation of APC by thrombin is impaired in hyperhomocysteinemia in monkeys and that hyperhomocysteinemia produces resistance to APC in monkeys, mice, and humans. In a randomized crossover study, cynomolgus monkeys were fed either a control diet or a hyperhomocysteinemic diet for 4 weeks. Plasma total homocysteine (tHcy) was approximately 2-fold higher when monkeys were on the hyperhomocysteinemic diet than when they were on the control diet (9.8 +/- 2.0 microM versus 5.6 +/- 1.0 microM; P <.05). After infusion of human thrombin (25 microg/kg of body weight), the peak level of plasma APC was 136 +/- 16 U/mL in monkeys fed the control diet and 127 +/- 13 U/mL in monkeys fed the hyperhomocysteinemic diet (P >.05). The activated partial thromboplastin time was prolonged to a similar extent by infusion of thrombin in monkeys fed the control diet and in those fed the hyperhomocysteinemic diet. The sensitivity of plasma FV to human APC was identical in monkeys on control diet and those on hyperhomocysteinemic diet. We also did not detect resistance of plasma FV to APC in hyperhomocysteinemic mice deficient in cystathionine beta-synthase (plasma tHcy, 93 +/- 16 microM) or in human volunteers with acute hyperhomocysteinemia (plasma tHcy, 45 +/- 6 microM). Our findings indicate that activation of protein C by thrombin and inactivation of plasma FVa by APC are not impaired during moderate hyperhomocysteinemia in vivo.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12200374     DOI: 10.1182/blood-2002-03-0727

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  7 in total

1.  Association between MTHFR C677T polymorphism and osteonecrosis of the femoral head: a meta-analysis.

Authors:  Xi-fu Shang; Hong Su; Wei-wei Chang; Chen-cheng Wang; Qin Han; Zhi-wei Xu
Journal:  Mol Biol Rep       Date:  2012-02-07       Impact factor: 2.316

2.  Enhanced susceptibility to arterial thrombosis in a murine model of hyperhomocysteinemia.

Authors:  Sanjana Dayal; Katina M Wilson; Lorie Leo; Erland Arning; Teodoro Bottiglieri; Steven R Lentz
Journal:  Blood       Date:  2006-06-27       Impact factor: 22.113

3.  The role of methylenetetrahydrofolate reductase C677T gene polymorphism as a risk factor for coronary artery disease: a cross-sectional study in the Sidoarjo Regional General Hospital.

Authors:  Hairudi Sugijo; Djanggan Sargowo; Edi Widjajanto; Rochmad Romdoni
Journal:  Pan Afr Med J       Date:  2022-03-15

Review 4.  Homocysteine, Vitamins B6 and Folic Acid in Experimental Models of Myocardial Infarction and Heart Failure-How Strong Is That Link?

Authors:  Zorislava Bajic; Tanja Sobot; Ranko Skrbic; Milos P Stojiljkovic; Nenad Ponorac; Amela Matavulj; Dragan M Djuric
Journal:  Biomolecules       Date:  2022-04-01

Review 5.  Molecular targeting of proteins by L-homocysteine: mechanistic implications for vascular disease.

Authors:  Alla V Glushchenko; Donald W Jacobsen
Journal:  Antioxid Redox Signal       Date:  2007-11       Impact factor: 8.401

6.  Association of MTHFR genetic polymorphisms with venous thromboembolism in Uyghur population in Xinjiang, China.

Authors:  Zhao Li; Umesh Yadav; Ailiman Mahemuti; Bao-Peng Tang; Halmurat Upur
Journal:  Int J Clin Exp Med       Date:  2015-10-15

Review 7.  Murine models of hyperhomocysteinemia and their vascular phenotypes.

Authors:  Sanjana Dayal; Steven R Lentz
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-06-12       Impact factor: 8.311

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.